Replies to post #144381 on NanoViricides Inc. (NNVC)

[KMBJN]

or 3) is unhappy with the arrangement but invests anyways.
I'm sure there are other things that investors feel about the arrangement, and they all are valid, not just what you think investors should feel about the arrangement.

Can't say I've seen any "rabid defense" of said arrangement over the last several years.

The way to judge the relationship is to ask what has Diwan from Theracour delivered to NNVC?

So far not very much, since he hasn't gotten anything with IND approval and into trials yet. He has delivered multiple potential candidates (that could rapidly be put out as topical herpecides for different HHVs and indications), but needs to prove that it is a viable developmental platform by getting the first nanoviricide into trials. He has had plenty of time, has recently raised more money (plus has an ATM deal for more), and it's crunch time. No more excuses? (though I'm sure Covid hampering required third parties/CROs and consultants, and developmental work focus on CoVCide will probably be listed).